Riskpilot← Back to searchSign inGet full accessREPONEX PHARMACEUTICALS A/S
A/SActiveCVR 30082346Slotsmarken 12, 1. thManufacture of pharmaceutical preparations · NACE 2120Est. 20062 employeeswww.reponex.dk
Revenue 2024
DKK 0
EBITDA margin
—
+19% vs 2023
Equity ratio
-241.9%
Financial strength
Net profit 2024
DKK -11,9M
+17% vs 2023
| Revenue | DKK 0 | — |
| EBITDA | DKK -13,5M | +19% |
| Net profit | DKK -11,9M | +17% |
| Total assets | DKK 3,6M | -83% |
| Equity | DKK -8,8M | -152% |
| Employees | 2 | — |
Legal name
REPONEX PHARMACEUTICALS A/S
CVR number
30082346
Legal form
Aktieselskab
NACE code
2120 · Manufacture of pharmaceutical preparations
Founded
4. december 2006
Share capital
DKK 849.868
Employees
2 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2024-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af direktøren og formanden for bestyrelsen i forening eller af den samlede bestyrelse.
Company purpose
Selskabets formål er at drive virksomhed med at udvikle lægemidler samt dermed beslægtede aktiviteter og at være Holding virksomhed for selskaber med tilsvaren-de formål.
Address
Slotsmarken 12, 1. th
Website
www.reponex.dk
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | 0 | -1.182 | 242 | -1.267 | 0 | 0 | 0 | 0 | — | 0 | 0 |
| Staff expenses | -0 | -0 | -0 | -0 | -0 | -543 | -125 | -119 | -95 | -0 | -0 | -0 | -0 |
| EBITDA | -9 | 217 | -602 | -1.133 | -300 | -1.887 | -685 | -1.947 | -2.145 | -8.840 | -12.043 | -16.600 | -13.507 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 | -0 | -652 | -390 | -157 | -3.763 | -0 | -0 | -0 |
| EBIT | -9 | 217 | -602 | -1.133 | -300 | -1.887 | -1.337 | -2.338 | -2.302 | -12.604 | -12.043 | -16.600 | -13.507 |
| Net financials | -15 | -67 | -81 | 199 | -119 | -108 | -260 | -21 | -81 | -251 | -22 | 21 | -251 |
| Profit before tax | -24 | -91 | -674 | -1.215 | -419 | -1.995 | -1.596 | -2.359 | -2.383 | -12.855 | -12.065 | -16.579 | -13.759 |
| Tax | -6 | -0 | -0 | -0 | -87 | -419 | -340 | -505 | -878 | -2.971 | -1.855 | -2.233 | -1.815 |
| Net profit | -18 | 150 | -683 | -934 | -332 | -1.576 | -1.257 | -1.854 | -1.505 | -9.883 | -10.210 | -14.346 | -11.943 |
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 940 | 2.002 | 3.085 | 2.895 | 7.940 | 7.895 | 9.694 | 17.502 | 20.409 | 28.708 | 19.984 | 21.662 | 3.631 |
| Equity | 80 | 230 | 1.469 | 536 | 5.230 | 3.654 | 2.397 | 14.933 | 13.428 | 27.371 | 17.379 | 16.757 | -8.785 |
| Long-term debt | 0 | 0 | 0 | 0 | 1.671 | 1.721 | 720 | 0 | 0 | 163 | 295 | 234 | 0 |
| Short-term debt | 860 | 1.772 | 1.310 | 2.110 | 384 | 1.907 | 6.577 | 1.388 | 5.492 | 1.174 | 2.311 | 4.671 | 12.416 |
| Total debt | 860 | 1.772 | 1.310 | 2.110 | 2.055 | 3.627 | 7.297 | 1.388 | 5.492 | 1.337 | 2.606 | 4.905 | 12.416 |
EBITDA margin
-1350700000.0%
This company
15.8%
Market median
-8548734277% vs market
20122024
Equity ratio
-241.9%
This company
38.2%
Market median
-733% vs market
20122024
Return on equity
-1194300000.0%
This company
18.4%
Market median
-6490760970% vs market
20122024
Net profit margin
-1194300000.0%
This company
8.1%
Market median
-14744444544% vs market
20122024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20122024
Debt / equity
1.41×
This company
0.62×
Market median
-127% vs market
20122024
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via CVR / Virk · Period 2016-01-01 – 2016-12-31
- Annual report 2015Filed via CVR / Virk · Period 2015-01-01 – 2015-12-31
- Annual report 2014Filed via CVR / Virk · Period 2014-01-01 – 2014-12-31
- Annual report 2013Filed via CVR / Virk · Period 2013-01-01 – 2013-12-31
- Annual report 2012Filed via CVR / Virk · Period 2012-01-01 – 2012-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
MS Management | Management | 2008 | — | — |
TK Chief Executive Officer | Chief Executive Officer | 2023 | — | — |
TB Management | Management | 2016 | — | — |
HL Chief Executive Officer | Chief Executive Officer | 2010 | — | — |
MT Management | Management | 2006 | — | — |
JS Management | Management | 2007 | — | — |
CH Chief Executive Officer | Chief Executive Officer | 2025 | — | — |
SB Chief Executive Officer | Chief Executive Officer | 2025 | — | — |
KS Chief Executive Officer | Chief Executive Officer | 2021 | — | — |
SG Chief Executive Officer | Chief Executive Officer | 2022 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2023 | — | — | |
| Board of Directors | 2023 | — | — | |
| Board of Directors | 2015 | — | — | |
| Board of Directors | 2016 | — | — | |
| Board of Directors | 2017 | — | — | |
| Chairman | 2015 | — | — | |
| Chairman | 2022 | — | — | |
| Board of Directors | 2018 | — | — | |
| Board of Directors | 2021 | — | — | |
| Deputy Chairman | 2021 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Pharma Equity Group A/S | Company | 100.0% | 100.0% | 2023 |
DANISH MEDICAL CONSULTS ApS | Company | 5.0% | 5.0% | 2018 |
Beier Holding ApS | Company | 10.0% | 10.0% | 2019 |
NIELS ERIK JESPERSEN HOLDING ApS | Company | 5.0% | 5.0% | 2019 |
CLINICURO ApS | Company | 5.0% | 5.0% | 2014 |
VULKAN INVEST ApS | Company | 5.0% | 5.0% | 2015 |
BIOPHARMA HOLDING ApS | Company | 20.0% | 20.0% | 2017 |
BREGNERØDVEJ AUTO ApS | Company | 5.0% | 5.0% | 2014 |
FINANSMANAGEMENT ApS | Company | 5.0% | 5.0% | 2015 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
NIELS ERIK JESPERSEN HOLDING ApS
REPONEX PHARMACEUTICALS A/S Board members of REPONEX PHARMACEUTICALS A/S also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Michael Secher | Management | 0 companies |
| Thomas Kaas Selsø | Chief Executive Officer | 0 companies |
| Torsten Bjørn | Management | 0 companies |
| Henrik Lasse Lindblad | Chief Executive Officer | 0 companies |
| Mikael Thiesen | Management | 0 companies |
| Jon Steffen Therkildsen | Management | 0 companies |
| Christian Henrik Tange | Chief Executive Officer | 0 companies |
| Sebastian Bo Jakobsen | Chief Executive Officer | 0 companies |
| Klaus Snej Jensen | Chief Executive Officer | 0 companies |
| Sigbjørn Georg Nielsen Kjærgård | Chief Executive Officer | 0 companies |
| Peter Mørch Eriksen | Board of Directors | 0 companies |
| Mette Zacho | Board of Directors | 0 companies |
| Henrik Bulskov | Board of Directors | 0 companies |
| Erik Lennard Vitting Skovbjerg | Board of Directors | 0 companies |
| Lisbeth Thyregod | Board of Directors | 0 companies |
| Jacob Rosenberg | Chairman | 0 companies |
| Christian Vinding Thomsen | Chairman | 0 companies |
| Charlotte Pahl | Board of Directors | 0 companies |
| Katrine Hoff Schlichtkrull | Board of Directors | 0 companies |
| Troels Peter Troelsen | Deputy Chairman | 0 companies |